Nasal universal vaccine boosts innate immunity to shield mice from multiple respiratory pathogens
A Stanford-led study describes an intranasal “universal vaccine” that activates the innate immune system to provide at least three months of protection in mice against SARS-CoV-2, other coronaviruses, and bacteria causing respiratory infections, while also dampening allergic responses. If safe and effective in humans, it could become a winter-wide first line of defense against diverse respiratory diseases.